511 related articles for article (PubMed ID: 8730759)
1. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759
[TBL] [Abstract][Full Text] [Related]
2. Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart.
Plandé J; Platel D; Tariosse L; Robert J
Toxicol Lett; 2006 Feb; 161(1):37-42. PubMed ID: 16129573
[TBL] [Abstract][Full Text] [Related]
3. Role of daunorubicinol in daunorubicin-induced cardiotoxicity as evaluated with the model of isolated perfused rat heart.
Platel D; Bonoron-Adèle S; Robert J
Pharmacol Toxicol; 2001 May; 88(5):250-4. PubMed ID: 11393585
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart.
Platel D; Pouna P; Bonoron-Adèle S; Robert J
Toxicol Appl Pharmacol; 2000 Mar; 163(2):135-40. PubMed ID: 10698671
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin.
Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
Cancer Chemother Pharmacol; 1995; 35(3):257-61. PubMed ID: 7805186
[TBL] [Abstract][Full Text] [Related]
6. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls.
Robert J
Cell Biol Toxicol; 2007 Jan; 23(1):27-37. PubMed ID: 17041747
[TBL] [Abstract][Full Text] [Related]
7. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin.
Platel D; Bonoron-Adèle S; Dix RK; Robert J
Br J Cancer; 1999 Sep; 81(1):24-7. PubMed ID: 10487608
[TBL] [Abstract][Full Text] [Related]
9. Effects of three new anthracyclines and doxorubicin on the rat isolated heart.
Chen ZM; Colombo T; Conforti L; Grazia Donelli M; Fiedorowicz RJ; Marchi S; Paolini A; Riva E; Zuanetti G; Latini R
J Pharm Pharmacol; 1987 Nov; 39(11):947-50. PubMed ID: 2892924
[TBL] [Abstract][Full Text] [Related]
10. Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart.
de Nigris F; Rienzo M; Schiano C; Fiorito C; Casamassimi A; Napoli C
Eur J Cancer; 2008 Feb; 44(3):334-40. PubMed ID: 18194856
[TBL] [Abstract][Full Text] [Related]
11. Cardiac safety of liposomal anthracyclines.
Safra T
Oncologist; 2003; 8 Suppl 2():17-24. PubMed ID: 13679592
[TBL] [Abstract][Full Text] [Related]
12. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors.
Robert J
Cardiovasc Toxicol; 2007; 7(2):135-9. PubMed ID: 17652818
[TBL] [Abstract][Full Text] [Related]
13. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
14. Cardiac safety of liposomal anthracyclines.
Ewer MS; Martin FJ; Henderson C; Shapiro CL; Benjamin RS; Gabizon AA
Semin Oncol; 2004 Dec; 31(6 Suppl 13):161-81. PubMed ID: 15717742
[TBL] [Abstract][Full Text] [Related]
15. [Dexrazoxane. Current status and prospectives of cardiotoxicity of chemotherapy].
Lopez M
Clin Ter; 1999; 150(1):37-49. PubMed ID: 10367544
[TBL] [Abstract][Full Text] [Related]
16. Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model.
Platel D; Pouna P; Bonoron-Adèle S; Robert J
Anticancer Drugs; 1999 Aug; 10(7):671-6. PubMed ID: 10507317
[TBL] [Abstract][Full Text] [Related]
17. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
Lopez M; Vici P
Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
[TBL] [Abstract][Full Text] [Related]
18. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
19. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Wiseman LR; Spencer CM
Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
[TBL] [Abstract][Full Text] [Related]
20. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.
Jirkovský E; Lenčová-Popelová O; Hroch M; Adamcová M; Mazurová Y; Vávrová J; Mičuda S; Šimůnek T; Geršl V; Štěrba M
Toxicology; 2013 Sep; 311(3):191-204. PubMed ID: 23831762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
